Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
    • Heat Biologics Mask
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics to Present at the 2018 BIO Investor Forum

Oct 10, 2018

Heat Biologics’ Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator

Oct 4, 2018

Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

Aug 29, 2018

Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update

Aug 14, 2018

Heat Biologics to Present at the 2018 BIO International Convention

May 30, 2018

Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update

May 15, 2018

Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering

May 7, 2018

Heat Biologics, Inc. Prices $18,000,000 Public Offering

May 3, 2018

Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110

Apr 18, 2018

Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform

Mar 26, 2018
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...25
    © 2021 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn